Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
allergan
3
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
biotech
national top stories
abbvie
alkermes
boston
bristol-myers squibb
buprenorphine
cariprazine
clinical data
crispr
cynthia collins
drugs
editas medicine
eli lilly
europe
europe blog main
europe top stories
fda
felipe jain
gene editing
genfit
gilead sciences
intercept pharmaceuticals
jess fiedorowicz
jessica jeffrey
karim calis
katrine bosley
ldl-c
leber congenital amaurosis
liver
liver disease
lumateperone
m health fairview
madrigal pharmaceuticals
What
medicine
3
×
drug
alkermes
allergan
antipsychotic
approved
benefits
blessing
bosley
caveats
ceo
check
clinical
commonly
crispr
cusp
data
depart
designed
disease
editas
editing
effect
experimental
fatty
favor
fda
gain
gene
horizon
humans
intercept
katrine
known
liver
marketed
million
nash
new
nonalcoholic
Language
unset
Current search:
allergan
×
medicine
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial